E-Cigarette Firm Targets Harm Reduction In Therapeutic Claim
This article was originally published in The Pink Sheet Daily
CN Creative’s plan to include harm reduction with smoking cessation in claims for its Nicadex electronic cigarette was key to Advent Life Sciences investing in the firm, which is prepared to ask U.K. regulators for approval this summer before applying in the U.S.
You may also be interested in...
FDA encourages disclosures at public hearings
Speakers at a workshop on nicotine-replacement therapy point abroad for guidance on expanding indications for smoking-cessation products as an FDA official says the agency likely will put the question before an advisory committee.
FDA sets ground rules for regulating electronic cigarettes in warning letters to five firms about unapproved smoking cessation claims and in a separate summary letter to an industry trade group